BR112023016440A2 - Formulações de ruc-4 estáveis - Google Patents

Formulações de ruc-4 estáveis

Info

Publication number
BR112023016440A2
BR112023016440A2 BR112023016440A BR112023016440A BR112023016440A2 BR 112023016440 A2 BR112023016440 A2 BR 112023016440A2 BR 112023016440 A BR112023016440 A BR 112023016440A BR 112023016440 A BR112023016440 A BR 112023016440A BR 112023016440 A2 BR112023016440 A2 BR 112023016440A2
Authority
BR
Brazil
Prior art keywords
ruc
formulations
stable
solid
range
Prior art date
Application number
BR112023016440A
Other languages
English (en)
Inventor
Yatindra Joshi
Original Assignee
Celecor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celecor Therapeutics Inc filed Critical Celecor Therapeutics Inc
Publication of BR112023016440A2 publication Critical patent/BR112023016440A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

formulações de ruc-4 estáveis. a presente invenção refere-se a formulações sólidas e líquidas de ruc-4 que são estáveis sob uma faixa de condições de armazenamento.
BR112023016440A 2021-02-17 2022-02-16 Formulações de ruc-4 estáveis BR112023016440A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150168P 2021-02-17 2021-02-17
PCT/US2022/016564 WO2022177962A1 (en) 2021-02-17 2022-02-16 Stable ruc-4 formulations

Publications (1)

Publication Number Publication Date
BR112023016440A2 true BR112023016440A2 (pt) 2023-10-10

Family

ID=82931621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016440A BR112023016440A2 (pt) 2021-02-17 2022-02-16 Formulações de ruc-4 estáveis

Country Status (8)

Country Link
EP (1) EP4294401A1 (pt)
JP (1) JP2024507293A (pt)
KR (1) KR20230157353A (pt)
CN (1) CN117597127A (pt)
AU (1) AU2022223560A1 (pt)
BR (1) BR112023016440A2 (pt)
CA (1) CA3211206A1 (pt)
WO (1) WO2022177962A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861350C (en) * 2012-01-16 2020-12-15 The Rockefeller University Thiadiazolo-pyrimidin-5-one derivatives as aiib.beta.3 antagonists
US11684622B2 (en) * 2018-06-19 2023-06-27 Celecor Therapeutics, Inc. Deuterated RUC-4

Also Published As

Publication number Publication date
WO2022177962A9 (en) 2022-10-13
WO2022177962A1 (en) 2022-08-25
CN117597127A (zh) 2024-02-23
KR20230157353A (ko) 2023-11-16
CA3211206A1 (en) 2022-08-25
JP2024507293A (ja) 2024-02-16
AU2022223560A1 (en) 2023-08-24
EP4294401A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
CU20190058A7 (es) Composiciones de aminoácidos relacionadas con mejoras de la función hepática
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
BR112019001976A2 (pt) inibidores da diacilglicerol aciltransferase 2
EA201890949A1 (ru) СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
CL2017000856A1 (es) Composición plastificante que comprende cicloalquilésteres de ácidos dicarboxílicos saturados y ésteres 1,2-ciclo-hexandicarboxílicos.
CO6341615A2 (es) Salicilatos acetilados con acidos grasos y sus usos.
BR112019001054A2 (pt) desinfetantes tópicos emolientes
BR112021012040A2 (pt) Molécula anti-pd-1/sirpa bifuncional
CL2021000328A1 (es) Inhibidores de transglutaminasa 2 (tg2)
BR112017022209A2 (pt) composição aquosa que compreende éster de ácido omega- aminocarboxílico e álcool graxo e seu uso
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
BR112021021048A2 (pt) Polipeptídeos que se ligam a cd33 e seus usos
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
WO2016137969A3 (en) Liquid levothyroxine formulations
BR112017011336A2 (pt) composição de resina epóxi curável
CO2022000700A2 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
BR112023018619A2 (pt) Inibidores de heteroaril de calicreína plasmática
BR112018009627A8 (pt) compostos contendo enxofre como solventes
BR112017008613A2 (pt) composição de concentrado para extensão de cadeia polimérica